Key result
mDIXON-Quant MRI detects higher cortex R2* values in moderate to severe CKD versus healthy volunteers.
Why the study?
Early stages of CKD are asymptomatic, and early detection is critical for early intervention and improving prognosis.
Does mDIXON-Quant imaging accurately detect early CKD and evaluate the degree of renal damage?
Observational (n=57)
Double-blind (radiologists blinded to clinical and imaging information)
No
Does mDIXON-Quant imaging accurately detect early CKD and evaluate the degree of renal damage?
Effect estimate: AUC 0.829 (95% CI 0.674-0.930)
Absolute Event Rate: 18.81% vs 15.38%
p-value: p=0.001
mDIXON-Quant MRI can non-invasively detect early chronic kidney disease and differentiate the severity of renal damage by quantifying cortical fat fraction and R2* values.
May support noninvasive CKD severity assessment; hypothesis-generating and leaves open early-detection utility pending prospective validation.
Background: Chronic kidney disease (CKD) is a complex syndrome with high morbidity and slow progression. Early stages of CKD are asymptomatic and lack of awareness at this stage allows CKD to progress through to advanced stages. Early detection of CKD is critical for the early intervention and prognosis improvement. Purpose: To assess the capability of mDIXON-Quant imaging to detect early CKD and evaluate the degree of renal damage in patients with CKD. Study type: Retrospective. Population: 35 patients with CKD: 18 cases were classifified as the mild renal damage group (group A) and 17 cases were classifified as the moderate to severe renal damage group (group B). 22 healthy volunteers (group C). Field strength/sequence: WI and mDIXON-Quant sequences. Assessment: Transverse relaxation rate (R2*) values and fat fraction (FF) values derived from the mDIXON-Quant were calculated and compared among the three groups. Statistical tests: The intra-class correlation (ICC) test; Chi-square test or Fisher's exact test; Shapiro-Wilk test; Kruskal Wallis test with adjustments for multiplicity (Bonferroni test); Area under the receiver operating characteristic (ROC) curve (AUC). The significance threshold was set at P < 0.05. Results: Cortex FF values and cortex R2* values were significantly different among the three groups (P=0.028, <0.001), while medulla R2* values and medulla FF values were not (P=0.110, 0.139). Cortex FF values of group B was significantly higher than that of group A (Bonferroni adjusted P = 0.027). Cortex R2* values of group A and group B were both significantly higher than that of group C (Bonferroni adjusted P = 0.012, 0.001). The AUC of cortex FF values in distinguishing group A and group B was 0.766. The diagnostic efficiency of cortex R2* values in distinguishing group A vs. group C and group B vs. group C were 0.788 and 0.829. Conclusion: The mDIXON-Quant imaging had a potential clinical value in early diagnosis of CKD and assessing the degree of renal damage in CKD patients.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2023) conducted an observational in Chronic kidney disease (n=57). mDIXON-Quant imaging vs. Healthy volunteers was evaluated on Cortex R2* values (moderate to severe CKD vs healthy volunteers) (AUC 0.829, 95% CI 0.674-0.930, p=0.001). mDIXON-Quant imaging demonstrated that cortex R2* values were significantly higher in patients with moderate to severe chronic kidney disease compared to healthy volunteers (AUC 0.829).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: